Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kekkonen, R.
Right arrow Articles by Tuominen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kekkonen, R.
Right arrow Articles by Tuominen, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 10, No. 2, pp. 287-292, 1995
© 1995 European Society of Human Reproduction and Embryology


research-article

Physiology: Effects of intermittent antiprogestin RU486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation

Raimo Kekkonen1, Horacio B. Croxatto2, Pekka Lähteenmäki1,3, Ana Maria Salvatierra2 and Juhani Tuominen4

1Steroid Research Laboratory, Department of Medical Chemistry PO Box 8, SF-00014 University of Helsinki, Helsinki, Finland 2Instituto Chileno de Medicina Reproductiva, Jose Ramon Gutierrez 295 Dipartmento 3, Santiago, Chile 4Department of Biostatistics, Medical Faculty, University of Turku, Lemminkäisenkatu 1 SF-20520 Turku, Finland

Correspondence: 3To whom correspondence should be addressed

The results of several studies have suggested an inhibitory effect of the antiprogestin RU486 on late stages of folliculogenesis and ovulation. To assess the feasibility of using this property to inhibit ovulation without losing cycle control, an intermittent administration of RU486 alternated with medroxyprogesterone acetate (MPA) was tested in a phase I study. RU486 at a dose of 50 mg/day was given on menstrual cycle days 9–11 and 27–29, and 10 mg/day of MPA was given on cycle days 17–26 for three consecutive cycles to six Finnish and five Chilean women. Blood samples were collected two to three times a week for serum progesterone and oestradiol assays in three treatment cycles. One control cycle and one post-treatment recovery cycle were also monitored by serum samplings. Ultrasonography was carried out to measure follicular diameters in the treatment cycles. In 29 of 32 cycles, bleeding commenced within 3 days after the last MPA pill intake. Out of 32 treatment cycles, 20 were without luteal activity (serum progesterone <9 nmol/l). Although 12 treatment cycles showed luteal activity (serum progesterone ≥9 nmol/l), a clear rupture of a pre-ovulatory follicle >15 mm, verified by ultrasonography, was seen in only one treatment cycle. During the treatment cycles with luteal activity (serum progesterone levels ≥9 nmol/1), serum oestradiol concentrations were significantly higher on cycle days 9–18 and significantly lower at the end of the cycle compared with the cycles without luteal activity. The regimen used in this study disturbed folliculogenesis and ovulation (apparently), and was able to provide good cycle control in the majority of the cycles.

Key words: antiprogestin RU486/intermittent administration/luteal activity/ovulation/progestins


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
A.M. van Heusden, S.R. Killick, H.J.T.C. Bennink, and B.C.J.M. Fauser
Single monthly administration of the anti-progestagen Org 31710 in users of the 75 {micro}g desogestrel progestagen-only pill: effects on pituitary-ovarian activity
Hum. Reprod., March 1, 2000; 15(3): 629 - 636.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.